New Developments (July 23–24, 2026): As the US temporary 10% Section 122 duties expired, the Trump administration announced permanent Section 301 tariffs across 60 trade partners. India successfully secured a reduced 10% rate (down from the proposed 12.5%) following bilateral engagement on supply-chain labor standards. Meanwhile, competing manufacturing economies like China, Japan, and parts of the EU face 12.5%. Furthermore, on July 21, the US announced a 2-year 0% tariff window on generic drugs starting August 1, 2026, granting Indian pharma exporters a crucial runway.
US tariffs on India went from 26% → 50% → 18% — and now stand at 10% under permanent Section 301 provisions. Textile stocks surged up to 20%, pharma rallied 3%, and IT got sentiment relief. Here is the full sector-by-sector breakdown and exactly what your SIPs should do next.
On February 2, 2026, President Trump posted on Truth Social announcing an interim deal, and Prime Minister Modi called it a "wonderful announcement." In a single move, the effective tariff on Indian goods entering the United States — which had climbed as high as 50% in August 2025 — was slashed to 18%, and has now been formalized into a 10% Section 301 rate in July 2026. The Gift Nifty surged 600 points on the initial news. Textile stocks hit upper circuits. Pharma stocks rallied. And investors across India needed to understand what this means for their portfolios.
This article is that complete guide. We cover the full tariff timeline, which sectors benefit and which face headwinds, where the Bilateral Trade Agreement (BTA) stands in July 2026, and the only thing that actually matters for retail investors: what should your SIPs and portfolio do?
"In twelve months, the effective US tariff on Indian goods shifted 26% → 50% → 18% → 10%. The investor who panicked at 50% sold at the bottom. The investor who understood the negotiating dynamics held on — and is now looking at a structural tailwind."
The Full Tariff Timeline: How We Got Here
Understanding where we are today requires knowing the full journey — because this deal did not come out of nowhere. It came after over a year of escalating pressure, retaliation threats, court challenges, and diplomatic back-channel work.
| Date | Event | Effective US Tariff on India |
|---|---|---|
| April 2025 | Trump announces "reciprocal tariff" on India | 26% |
| April–August 2025 | 90-day pause for most countries; India-US talks begin | 26% (paused, then reinstated) |
| August 2025 | US adds 25% punitive tariff (citing Russian oil purchases) | ~50% effective |
| Aug 2025 – Jan 2026 | Intense negotiations; India offers energy + farm concessions | ~50% |
| Feb 2, 2026 | Modi-Trump call — interim deal agreed (cuts to 18%) | 18% |
| Feb 6, 2026 | White House Executive Order signed; 25% penal tariff removed | 18% |
| Feb 20, 2026 | 10% temporary 150-day Section 122 duty introduced globally | 10% temporary |
| July 21, 2026 | Phased Generic Drug Tariff plan announced (0% for 2 yrs) | 0% generic pharma (until 2028) |
| July 23–24, 2026 | Section 301 "Forced Labour" Tariffs finalized | 10% Permanent (India down from 12.5%) |
The tariff reductions were negotiated around strategic trade commitments. India committed to: (1) stop purchasing Russian Federation crude oil, (2) commit to buying $500 billion+ of US energy, technology, agricultural, and coal products, and (3) update labor safeguards in domestic supply chains (enacted via India's Foreign Trade Policy update on June 14). This directly helped India win the lower 10% tariff band over competitors facing 12.5%.
Sector Winners: Who Benefits Most
The 10% tariff rate combined with relative differentials against other Asian markets creates distinct sector winners. The biggest beneficiaries are export-oriented sectors with direct US revenue dependencies.
Textiles & Apparel
32% of India's textile exports go to the US. The tariff reduction restores pricing competitiveness on par with Bangladesh and Sri Lanka, and ahead of China/Vietnam. Stock market reaction: Gokaldas Exports surged up to 20%, KPR Mill +10%, Arvind +7%, Vardhman +8%, Welspun Living +3%, and Raymond Lifestyle +5%.
Pharma & Generics
The US is India's largest export market (~$9.7B annually). The July 21 announcement guarantees a 0% tariff on generic drugs until 2028 before any onshore escalation occurs. Nifty Pharma rose 3%+ post-announcement, benefiting Sun Pharma, Dr. Reddy's, Cipla, and Divi's Labs.
IT & Tech Services
IT services are non-tangible and not subject to physical product tariffs. However, tariff clarity reduces fears of a US corporate recession. TCS, Infosys, and Wipro benefit from stabilized IT spending budgets among Fortune 500 US enterprise clients.
Gems, Jewellery & Engineering
India is a premier exporter of gems, jewellery, and precision engineering components. Retaining a 10% tariff advantage over 12.5% competitors enhances margin predictability and order inflows from US importers.
Sectors Facing Headwinds: The Other Side of the Trade Alignment
Trade agreements involve commercial trade-offs. Concessions made to secure favorable export tariffs create structural cost shifts in specific domestic sectors.
| Sector | Headwind / Shift | Investor Implication |
|---|---|---|
| Agriculture (Domestic) | India agreed to lower barriers on US agricultural inputs (pulses, soy, specialty farm products). | Domestic farm commodity margins under pressure; monitor rural FMCG and fertilizer earnings. |
| Oil & Refining | Pivoting away from discounted Russian crude toward market-rate US and Middle East energy supplies. | Input cost normalization for PSU refiners (HPCL, BPCL, IOC); gross refining margins (GRMs) under review. |
| Metals & Heavy Derivatives | Steel, aluminum, and copper face ongoing Section 232 tariffs (25% to 50% depending on processing). | Requires strict tracking of US-sourced raw materials for duty relief. |
| IT (Macro Risk) | If US economic growth slows despite trade stability, discretionary tech spending remains modest. | Analysts project modest Tier-1 revenue growth until US capital expenditure cycles fully accelerate. |
While the 10% Section 301 tariff is now active, the formal Bilateral Trade Agreement (BTA) negotiations continue to evolve. Investors must track official export data and quarterly corporate earnings over Q2 and Q3 FY27 to verify order volume translation.
What Should Your SIPs Do? A Practical Framework
Most retail investors hold equity through diversified mutual funds rather than tactical single-stock bets. The core question is how trade policy affects long-term systematic investment plans (SIPs).
Maintain regular SIPs without interruption. Well-managed Flexi-Cap funds maintain dynamic sector allocations across IT (15–20%), Pharma (6–10%), and Capital Goods. Fund managers naturally rebalance weightings into export beneficiaries, allowing your systematic investments to capture rupee-cost averaging automatically.
Your Investor Action Plan
5 Steps to Position Your Portfolio for Trade Policy Outcomes
Review Your Portfolio Strategy
Want to evaluate how global tariff developments impact your mutual fund portfolio? Book a consultation with Jasvinder Singh (AMFI ARN-344268).
NovaRock Advisory | AMFI ARN-344268 | IRS PTIN P03472019 | Kurukshetra, Haryana
Disclaimer: This article is for educational purposes only and does not constitute personalized investment advice or a recommendation to buy or sell any security. All data on tariffs, stock movements, and sector performance is sourced from publicly available official trade notifications and financial news as of July 27, 2026. Past performance of any sector or stock is not a guarantee of future returns. Mutual fund investments are subject to market risks. Please read all scheme-related documents carefully before investing. Jasvinder Singh is AMFI Registered (ARN-344268) and IRS Registered Tax Preparer (PTIN P03472019).